International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer - 12/10/16

Doi : 10.1016/S1470-2045(16)30369-2

Dominique Farge, ProfMD ^a,^b,^⁎ , Henri Bounameaux, ProfMD ^c, Benjamin Brenner, ProfMD ^d, Francis Cajfinger, MD ^e, Philippe Debourdeau, MD ^f, Alok A Khorana, ProfMD ^g, Ingrid Pabinger, ProfMD ^h, Susan Solymoss, MD ⁱ, James Douketis, ProfMD ^j, Ajay Kakkar, ProfPhD ^k,^l

^a Assistance Publique-Hôpitaux de Paris, Internal Medicine: Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Paris, France

^b Sorbonne Paris Cité, Paris 7 Diderot University, Paris, France

^c Division of Angiology and Hemostasis, University Hospitals of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland

^d Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

^e Assistance Publique-Hôpitaux de Paris, Service d’oncologie, Hôpital Pitié-Salpêtrière, Paris, France

^f Institut Sainte Catherine, Avignon, France

^g Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

^h Clinical Division of Hematology and Hemostaseology, Department of Internal Medicine, Medical University Vienna, Vienna, Austria

ⁱ Department of Medicine, McGill University, Montreal, QC, Canada

^j Department of Medicine, McMaster University, Hamilton, ON, Canada

^k Thrombosis Research Institute, London, UK

^l University College London, London, UK

^* Correspondence to: Prof Dominique Farge, Assistance Publique-Hôpitaux de Paris, Internal Medicine: Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Paris 75010, France Correspondence to: Prof Dominique Farge Assistance Publique-Hôpitaux de Paris Internal Medicine: Autoimmune and Vascular Disease Unit Saint-Louis Hospital Paris 75010 France

Summary

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at an increased risk of developing VTE and are more likely to have a recurrence of VTE and bleeding while taking anticoagulants. Management of VTE in patients with cancer is a major therapeutic challenge and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cancer (ITAC-CME), established to reduce the global burden of VTE in patients with cancer, published international guidelines for the treatment and prophylaxis of VTE and central venous catheter-associated thrombosis. The rapid global adoption of direct oral anticoagulants for management of VTE in patients with cancer is an emerging treatment trend that needs to be addressed based on the current level of evidence. In this Review, we provide an update of the ITAC-CME consensus recommendations based on a systematic review of the literature ranked according to the Grading of Recommendations Assessment, Development, and Evaluation scale. These guidelines aim to address in-hospital and outpatient cancer-associated VTE in specific subgroups of patients with cancer.

Le texte complet de cet article est disponible en PDF.

Plan

Export

Vol 17 - N° 10

P. e452-e466 - octobre 2016 Retour au numéro

Article précédent

Treatment of low-risk ductal carcinoma in situ: is nothing better than something?
John R Benson, Ismail Jatoi, Masakazu Toi

| Article suivant

Incorrect catheter placement for drainage of malignant pericardial effusion
Davorka Murši?, Marta Korši?, Sonja Badovinac, Miroslav Murši?, Marko Jakopovi?, Miroslav Samaržija

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer - 12/10/16

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL